MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024
MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading cell-engineering focused company, has announced it will release its third quarter 2024 financial results after the U.S. market close on Wednesday, November 6th, 2024. The company, which provides enabling platform technologies for cell therapeutics and bioprocessing applications, will host a conference call to discuss the financial results at 4:30 p.m. Eastern Time on the same day.
Investors interested in participating in the earnings conference call are required to register online, with registration recommended at least a day in advance. A live and archived webcast of the event will be available on the 'Events' section of MaxCyte's investor relations website at https://investors.maxcyte.com/.
MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), una delle principali aziende focalizzate sull'ingegneria cellulare, ha annunciato che rilascerà i suoi risultati finanziari del terzo trimestre 2024 dopo la chiusura del mercato statunitense il mercoledì 6 novembre 2024. L'azienda, che fornisce tecnologie di piattaforma abilitanti per le terapie cellulari e le applicazioni di bioprocessing, ospiterà una conferenza telefonica per discutere i risultati finanziari alle 16:30 ora orientale dello stesso giorno.
Gli investitori interessati a partecipare alla conferenza telefonica sugli utili sono tenuti a registrarsi online, con registrazione consigliata almeno un giorno in anticipo. Un webcast dal vivo e archiviato dell'evento sarà disponibile nella sezione 'Eventi' del sito web delle relazioni con gli investitori di MaxCyte all'indirizzo https://investors.maxcyte.com/.
MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), una de las principales empresas centradas en la ingeniería celular, ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 después del cierre del mercado estadounidense el miércoles 6 de noviembre de 2024. La empresa, que proporciona tecnologías de plataforma que facilitan las aplicaciones de terapias celulares y bioprocesamiento, organizará una llamada de conferencia para discutir los resultados financieros a las 4:30 p.m. hora del Este el mismo día.
Los inversionistas interesados en participar en la conferencia de ganancias deben registrarse en línea, recomendándose la registración al menos un día antes. Se dispondrá de una transmisión web en vivo y grabada del evento en la sección 'Eventos' del sitio de relaciones con los inversionistas de MaxCyte en https://investors.maxcyte.com/.
맥사이타, Inc. (NASDAQ: MXCT; LSE: MXCT), 세포 공학을 전문으로 하는 선도 기업으로, 2024년 3분기 재무 결과를 2024년 11월 6일 수요일 미국 시장 마감 후 발표할 것이라고 발표했습니다. 세포 치료 및 바이오 프로세싱 응용을 위한 플랫폼 기술을 제공하는 이 회사는 같은 날 동부 표준시 오후 4시 30분에 재무 결과를 논의하기 위한 컨퍼런스 콜을 개최할 예정입니다.
실적 발표 전화 회의에 참여하고자 하는 투자자는 온라인으로 등록해야 하며, 등록은 최소 하루 전에 권장됩니다. 해당 이벤트의 생중계 및 아카이브 웹캐스트는 MaxCyte의 투자자 관계 웹사이트 '이벤트' 섹션에서 확인할 수 있습니다: https://investors.maxcyte.com/.
MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), une entreprise leader dans le domaine de l'ingénierie cellulaire, a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 après la clôture du marché américain le mercredi 6 novembre 2024. L'entreprise, qui fournit des technologies de plateforme permettant les thérapies cellulaires et les applications de bioprocédés, animera une conférence téléphonique pour discuter des résultats financiers à 16h30, heure de l'Est le même jour.
Les investisseurs intéressés à participer à la conférence téléphonique sur les résultats sont tenus de s'inscrire en ligne, l'inscription étant recommandée au moins un jour à l'avance. Une webdiffusion en direct et archivée de l'événement sera disponible dans la section 'Événements' du site web des relations avec les investisseurs de MaxCyte à l'adresse https://investors.maxcyte.com/.
MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), ein führendes Unternehmen im Bereich Zelltechnik, hat angekündigt, dass es seine Finanzergebnisse für das dritte Quartal 2024 nach Marktschluss in den USA am Mittwoch, den 6. November 2024 veröffentlichen wird. Das Unternehmen, das Plattformtechnologien für Zelltherapien und Bioprozessanwendungen bereitstellt, wird am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz zur Diskussion der Finanzergebnisse abhalten.
Investoren, die an der Telefonkonferenz zu den Gewinnen teilnehmen möchten, müssen sich online registrieren, wobei eine Registrierung mindestens einen Tag im Voraus empfohlen wird. Eine Live- und Archiv-Webcast-Veranstaltung wird im 'Events'-Bereich der Investor-Relations-Website von MaxCyte unter https://investors.maxcyte.com/ verfügbar sein.
- None.
- None.
ROCKVILLE, Md., Oct. 11, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced that it will release financial results for the third quarter 2024 after the U.S. market close on Wednesday, November 6th, 2024. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.
Earnings Conference Call Details
Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at https://investors.maxcyte.com/.
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X and LinkedIn.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
US Media Relations
Spectrum Science
Jordan Vines
jvines@spectrumscience.com
+1 540-629-3137
Nominated Adviser and Joint Corporate Broker
Panmure Liberum
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR Adviser
ICR Consilium
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com
FAQ
When will MaxCyte (MXCT) release its Q3 2024 financial results?
What time is MaxCyte's (MXCT) Q3 2024 earnings conference call?
How can investors access MaxCyte's (MXCT) Q3 2024 earnings call?
Where can I find the webcast for MaxCyte's (MXCT) Q3 2024 earnings call?
